Cancer Causes and Control:绝经后女性2型糖尿病与胃肠肿瘤有关

2012-06-05 魏冬 医学论坛网

     美国研究人员5月24日在线发表于《癌症病因与控制》(Cancer Causes and Control)一项研究表明,在绝经后女性中,2型糖尿病与肝、胰腺、结肠和直肠癌风险显著升高有关。   该研究对参与女性健康倡议(WHI)的145765名50~79岁的绝经后女性进行了为期10.3年的随访,并采用考克斯(Cox)比例风险回归模型分析了胃肠肿瘤与糖尿病的

  inserted image

  美国研究人员5月24日在线发表于《癌症病因与控制》(Cancer Causes and Control)一项研究表明,在绝经后女性中,2型糖尿病与肝、胰腺、结肠和直肠癌风险显著升高有关。

  该研究对参与女性健康倡议(WHI)的145765名50~79岁的绝经后女性进行了为期10.3年的随访,并采用考克斯(Cox)比例风险回归模型分析了胃肠肿瘤与糖尿病的相关性。

  结果显示,入组时已确诊的糖尿病与肝[风险比(HR)=2.97,95%可信区间(CI)=1.66~5.32]、胰腺(HR=1.62,95%CI=1.15~2.30)、结肠(HR=1.38,95%CI=1.14~1.66)和直肠癌风险(HR=1.87,95%CI=1.22~2.85)升高相关。

  糖尿病严重度似乎与肝、胰腺和直肠而非结肠癌风险的相关性更强。

  糖尿病与胆管、食管和胃癌无显著相关性。

      

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2026073, encodeId=5ef420260e384, content=<a href='/topic/show?id=05ed83306b7' target=_blank style='color:#2F92EE;'>#胃肠肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83306, encryptionId=05ed83306b7, topicName=胃肠肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Thu Oct 11 10:02:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256969, encodeId=ddf812569694c, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526595, encodeId=fa9c1526595f1, content=<a href='/topic/show?id=2fe6e88863a' target=_blank style='color:#2F92EE;'>#绝经后女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78886, encryptionId=2fe6e88863a, topicName=绝经后女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b55511745984, createdName=chenhongpeng, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569680, encodeId=9531156968047, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631466, encodeId=2b7b1631466d5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2026073, encodeId=5ef420260e384, content=<a href='/topic/show?id=05ed83306b7' target=_blank style='color:#2F92EE;'>#胃肠肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83306, encryptionId=05ed83306b7, topicName=胃肠肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Thu Oct 11 10:02:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256969, encodeId=ddf812569694c, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526595, encodeId=fa9c1526595f1, content=<a href='/topic/show?id=2fe6e88863a' target=_blank style='color:#2F92EE;'>#绝经后女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78886, encryptionId=2fe6e88863a, topicName=绝经后女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b55511745984, createdName=chenhongpeng, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569680, encodeId=9531156968047, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631466, encodeId=2b7b1631466d5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2026073, encodeId=5ef420260e384, content=<a href='/topic/show?id=05ed83306b7' target=_blank style='color:#2F92EE;'>#胃肠肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83306, encryptionId=05ed83306b7, topicName=胃肠肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Thu Oct 11 10:02:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256969, encodeId=ddf812569694c, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526595, encodeId=fa9c1526595f1, content=<a href='/topic/show?id=2fe6e88863a' target=_blank style='color:#2F92EE;'>#绝经后女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78886, encryptionId=2fe6e88863a, topicName=绝经后女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b55511745984, createdName=chenhongpeng, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569680, encodeId=9531156968047, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631466, encodeId=2b7b1631466d5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2026073, encodeId=5ef420260e384, content=<a href='/topic/show?id=05ed83306b7' target=_blank style='color:#2F92EE;'>#胃肠肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83306, encryptionId=05ed83306b7, topicName=胃肠肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Thu Oct 11 10:02:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256969, encodeId=ddf812569694c, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526595, encodeId=fa9c1526595f1, content=<a href='/topic/show?id=2fe6e88863a' target=_blank style='color:#2F92EE;'>#绝经后女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78886, encryptionId=2fe6e88863a, topicName=绝经后女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b55511745984, createdName=chenhongpeng, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569680, encodeId=9531156968047, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631466, encodeId=2b7b1631466d5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
    2012-06-07 dongjia2015
  5. [GetPortalCommentsPageByObjectIdResponse(id=2026073, encodeId=5ef420260e384, content=<a href='/topic/show?id=05ed83306b7' target=_blank style='color:#2F92EE;'>#胃肠肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83306, encryptionId=05ed83306b7, topicName=胃肠肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Thu Oct 11 10:02:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256969, encodeId=ddf812569694c, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526595, encodeId=fa9c1526595f1, content=<a href='/topic/show?id=2fe6e88863a' target=_blank style='color:#2F92EE;'>#绝经后女性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78886, encryptionId=2fe6e88863a, topicName=绝经后女性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b55511745984, createdName=chenhongpeng, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569680, encodeId=9531156968047, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631466, encodeId=2b7b1631466d5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Thu Jun 07 10:02:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
    2012-06-07 zxxiang

相关资讯

ADA/EASD 2012年糖尿病指南解读和下载

  美国糖尿病学会(ADA,American Diabetes Association)和欧洲糖尿病研究协会(EASD,European Association for the Study of Diabetes)发表有关2型糖尿病治疗的最新立场声明,强调以患者为中心的治疗。      新指南的主要建议:   ? 必须根据患者具体特点制定个体化的血糖目标和降血糖治疗方

新指南勾画糖尿病管理地图:T2DM治疗步入患者为中心模式

  ADA/EASD发布立场声明,强调T2DM治疗目标和策略应个体化   美国糖尿病学会(ADA)与欧洲糖尿病研究学会(EASD)联合发布关于2型糖尿病(T2DM)高血糖管理的立场声明,强调以患者为中心的个体化治疗,并提出降糖策略推荐意见(图1)。声明4月19日在线发表于《糖尿病护理》(Diabetes Care)。(查看指南)   T2DM血糖管理日趋复杂,其原因包括数量和种类增多的药物

2012ADA/EASD立场声明-2型糖尿病患者的高血糖管理:以患者为中心的治疗

2012ADA+EASD立场声明-2型糖尿病患者的高血糖管理-以患者为中心的治疗.pdf 美国糖尿病学会(ADA)和欧洲糖尿病研究协会(EASD)联合发布立场声明,强调对2型糖尿病患者的高血糖进行个体化的治疗。这一最新指南于4月19日在线发表于Diabetes Care和Diabetologia。 新指南建议如下:   ? 必须根据患者具体特点制定个体化的血糖目标和降血糖治疗方案;

糖尿病高血压是老年动脉僵硬度增高的影响因素

  近日,北京大学第三医院老年内科刘喆、王海宁、王峥嵘等人共同发表论文,旨在评价老年高血压和(或)糖尿病患者动脉僵硬度及其影响因素。研究指出,糖尿病、高血压是老年人动脉僵硬度增高的影响因素,而高血糖对老年人动脉僵硬度的影响可能起了更重要的作用。血糖、平均动脉压、脉压、超每C反应蛋白、低密度脂蛋白胆固醇均是影响动脉僵硬度的独立危险因素。该文发表在2012年第31卷第1期《中华老年医学杂志》上。  

[ACCE2012]利拉利汀对非裔2型糖尿病患者安全有效

   一项纳入226例非裔2型糖尿病患者的多中心、随机、安慰剂对照试验显示,Linagliptin(利拉利汀)治疗与高血糖显著改善相关。   美国小石城阿肯色糖尿病与内分泌中心的医学研究主管James R. Thrasher博士在第21届美国临床内分泌医师协会年会(AACE2012, 5月23~27日, 美国费城)上报告了这项研究,他介绍到,非裔美国人一生中发生糖尿病的可能性增加77%

Diabetes Care: 运动疗法有利于2型糖尿病患者血糖控制

  荷兰学者研究发现,30分钟中等强度的耐力训练可降低2型糖尿病(T2DM)患者高血糖的出现几率。研究发表于《糖尿病护理》[Diabetes Care 2012, 35(5):948]。   该研究纳入30例2型糖尿病患者[年龄(60±1)岁,体质指数(30.4±0.7) kg/m2,糖化血红蛋白为(7.2 ± 0.2)%]。运动方式采